A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.

Blood
S C GoldmanMitchell S Cairo

Abstract

Standard therapy in the United States for malignancy-associated hyperuricemia consists of hydration, alkalinization, and allopurinol. Urate oxidase catalyzes the enzymatic oxidation of uric acid to a 5 times increased urine soluble product, allantoin. Rasburicase is a new recombinant form of urate oxidase available for clinical evaluation. This multicenter randomized trial compared allopurinol to rasburicase in pediatric patients with leukemia or lymphoma at high risk for tumor lysis. Patients received the assigned uric acid-lowering agent for 5 to 7 days during induction chemotherapy. The primary efficacy end point was to compare the area under the serial plasma uric acid concentration curves during the first 96 hours of therapy (AUC(0-96)). Fifty-two patients were randomized at 6 sites. In an intent-to-treat analysis, the mean uric acid AUC(0-96) was 128 +/- 70 mg/dL.hour for the rasburicase group and 329 +/- 129 mg/dL.hour for the allopurinol group (P <.0001). The rasburicase versus allopurinol group experienced a 2.6-fold (95% CI: 2.0-3.4) less exposure to uric acid. Four hours after the first dose, patients randomized to rasburicase compared to allopurinol achieved an 86% versus 12% reduction (P <.0001) of initial plasma u...Continue Reading

References

Jun 1, 1974·Postgraduate Medicine·C Pochedly
Mar 3, 1966·The New England Journal of Medicine·R C DeConti, P Calabresi
Jan 1, 1982·The Journal of Pediatrics·G MaseraM Recchia
Apr 1, 1980·The American Journal of Medicine·L F CohenJ L Ziegler
Jan 1, 1993·Medical and Pediatric Oncology·S F Bilgrami, B G Fallon
Feb 1, 1993·The American Journal of Medicine·K R Hande, G C Garrow
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W P BowmanS Murphy
Apr 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R V SmalleyJ A Hohneker

❮ Previous
Next ❯

Citations

Dec 8, 2004·Der Internist·M Krych
Feb 2, 2008·Pediatric Radiology·Melissa A HilmesPeter J Strouse
Jan 30, 2008·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Ludwig Patzer
Nov 26, 2009·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·David J HobbsTimothy E Bunchman
Nov 18, 2011·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Alisa A Acosta, Ronald J Hogg
May 24, 2012·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Alejandro BalestracciIsmael Toledo
Aug 12, 2006·Current Oncology Reports·Neerav N Shukla, Tanya M Trippett
Apr 3, 2003·Cancer Treatment Reviews·Elizabeth RaetzMitchell S Cairo
Jul 17, 2008·Supportive Cancer Therapy·Kesava ReddyVinay K Jain
Aug 9, 2006·Nature Clinical Practice. Oncology·Elvira RampelloMariano Malaguarnera
Dec 22, 2007·Nature Reviews. Drug Discovery·Benjamin LeaderDavid E Golan
Jul 1, 2009·Nature Reviews. Nephrology·Vaibhav SahniZiauddin Ahmed
May 13, 2011·The New England Journal of Medicine·Scott C HowardChing-Hon Pui
Sep 9, 2010·Proceedings of the National Academy of Sciences of the United States of America·William S StevensonWarren S Alexander
Oct 22, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S Vadhan-RajJ E Romaguera
Jan 28, 2005·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Bruno Vogt
Dec 20, 2002·Current Opinion in Oncology·Yaddanapudi Ravindranath
Nov 18, 2005·Current Opinion in Critical Care·Miet SchetzThomas Golper
Feb 7, 2007·Current Opinion in Rheumatology·Eliseo Pascual, Francisca Sivera
May 14, 2009·Current Opinion in Oncology·Michael Darmon, Elie Azoulay
Jun 22, 2010·American Journal of Therapeutics·Andrew Whelton
Nov 21, 2009·Current Opinion in Pediatrics·Rachel S BercovitzStephen P Hunger
Oct 15, 2005·BMJ : British Medical Journal·Roberta JoppiSilvio Garattini
Dec 17, 2008·Hematology·Archibald S Perkins, Jonathan W Friedberg
Dec 15, 2012·Journal of Hematology & Oncology·Ali McBride, Peter Westervelt
Jun 15, 2010·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Keiji Ohno, Kazuji Tawara
Mar 31, 2007·International Journal of Medical Sciences·Lisa Cammalleri, Mariano Malaguarnera
Nov 9, 2010·International Journal of Clinical Pharmacy·T BautersB De Moerloose
Mar 3, 2011·International Journal of Clinical Pharmacy·T BautersB De Moerloose
Aug 8, 2014·Pediatric Emergency Care·Rebekah A BurnsSally L Reynolds
Jun 11, 2014·Pharmacogenetics and Genomics·Ellen M McDonaghTeri E Klein
Mar 5, 2014·Anales de pediatría : publicación oficial de la Asociación Española de Pediatría (A.E.P.)·M R Pavo GarcíaJ L Vivanco Martínez
Apr 29, 2010·Current Rheumatology Reports·Naomi Schlesinger
May 16, 2012·Critical Care Medicine·Michael T McCurdy, Carl B Shanholtz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.